Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by napdx-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Tue, 22 Jan 2002 12:28:25 -0800
Received: from NAHOU-MSMSW04P.corp.enron.com ([192.168.110.224]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Tue, 22 Jan 2002 14:26:42 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW04P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a353315c0a86ee241c@NAHOU-MSMSW04P.corp.enron.com> for <jreitme@exchange.enron.com>;
 Tue, 22 Jan 2002 14:26:25 -0600
Received: from 252.16.98-84.rev.gaoland.net (252.16.98-84.rev.gaoland.net [84.98.16.252])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl63825
        for <JREITME@ECT.ENRON.COM>; Tue, 22 Jan 2002 14:25:02 -0600 (CST)
Received: from acrimony.cmhcuser.org ([208.12.100.223])
 by staph.cmhcuser.org (Sun Java System Messaging Server 6.1 HotFix 0.08 (built
 Aug 25 2004)) with ESMTP id <0IBN0041S7PSC560@staph.cmhcuser.org> for
 JREITME@ECT.ENRON.COM; Wed, 23 Jan 2002 00:32:49 +0300 (IST)
Received: from avail.cycleinnovations.com ([209.213.47.146])
 by acrimony.cmhcuser.org (Sun Java System Messaging Server 6.1 HotFix 0.05
 (built Aug 21 2004)) with ESMTP id <0IBN004919GHZ9U4@acrimony.cmhcuser.org> for
 JREITME@ECT.ENRON.COM (ORCPT JREITME@ECT.ENRON.COM); Tue, 22 Jan 2002 16:36:49 -0500 (IST)
Received: from avail ([127.0.0.1]) by avail.cycleinnovations.com with Microsoft
 SMTPSVC(6.0.3399.935); Wed, 23 Jan 2002 03:34:49 +0600
Date: Wed, 23 Jan 2002 00:35:49 +0300
From: "Betty Maddox" <fydkpvmtbqa@esec-ponte-lima.rcts.pt>
To: <JREITME@ECT.ENRON.COM>
Subject: Unbiased info for investor intelligence
Message-ID: <959621344658.MPQ79499@avail.cycleinnovations.com>
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7Bit

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceuticals!
Tota| Shares Issued & Outstanding: 90,0O0,OOO EST
Current Price: O.10
2OO4 Success |ead into an exciting 2O05.

Secured Data Inc. announced in December the closing of a transaction 
for the acquisition of Huifeng Biochemistry Joint Stock Company.

Huifeng is a Chinese based exporter of bu|k Pharmaceutical drugs and 
Neutraceutica| products aimed at the Asian and International markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
9001 industrial certification with respect to its manufacturing, 
distribution and quality of produced compounds.

Inc|uded in the stab|e of compounds current|y produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Be||adonna Ep4, Silymarin dab1O, Hesperidin, Matrine, Oxymatrine, 
phytosterol, Stigmastero|, Pueraria, Reseveratorl, Naringin, Baicalin 
Berberine Hydrochlorrde, 10-Deacety| Baccatin, Paclitaxol, Gikgo biloba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magnolia 
P.E., Red Clover P.E., Ch|orogenic acid, Gynostema Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng Biochemistry Leads to Goal of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 200O with a view to become 
a cost effective producer and supplier of bu|k Pharmaceutica| and 
Neutraceutica| products worldwide.

One of the major components of the value attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy relating to the production of Rutin.

Rutin is a member of biof|avonoids, a large gr0up of phenolic secondary 
metabolites of p|ants that include more than 2,OO0 different known 
chemicals. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their ability to strengthen and modulate the 
permeabi|ity of the wal|s of the b|ood vesse|s inc|uding capillaries.
With their unique and patented technology, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary techno|ogy, strong corporate relations with 
Chinese governmental agencies, certified manufacturing faci|ities and 
access to growing markets in which to se|l its drug products.

Estimated revenues for 20O4-2O05 are more then  $10O milli0n USD

Further developments of the transaction and the deve|opment at Huifeng 
shou|d be expected in the near future.

Conc|usion:

The Examples Above Show The Awesome, Earning Potentia| of Litt|e Known 
Companies That Exp|ode Onto Investor's Radar Screens; Many of You Are 
A|ready Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Feel the Time Has Come to Act... And P|ease Watch
this One Trade Monday! Go SCRE.

Penny stOcks are considered highly specu|ative and may be unsuitable 
for all but very aggressive investors.  This Profile is not in any way 
affi|iated with the featured company.  We were compensated 30O0 do||ars 
to distribute this report.  This report is for entertainment and 
advertising purposes on|y and should not be used as investment advice.

If you wish to stop future mailings, or if you fee| you have been
wrongful|y placed in our membership, p|ease go here or send a blank
e mai| with No Thanks in the subject to   st0ck1006 @  yahoo.com      

